All In Biotech

Drug Trial Radar · NCT05975073

A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors

A Phase 1/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Anvumetostat in Combination With IDE397 in Subjects With Advanced MTAP-null Solid Tumors

Last checked: Nov 19, 2026Latest source record: Apr 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

53

Actual

Start

Aug 1, 2023

Primary completion

Feb 25, 2026

Study completion Mar 26, 2026

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Aug 3, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main aims of this study are to evaluate the safety and tolerability, and to determine the maximum tolerated dose (MTD) or the recommended combination dose of Anvumetostat in combination with IDE397 in adult participants with metastatic or locally advanced MTAP-null solid tumors, and to evaluate the preliminary anti-tumor activity of anvumetostat in combination with IDE397 in adult participants with metastatic or locally advanced MTAP-null Non-Small-Cell Lung Cancer (NSCLC).

Conditions

  • MTAP-null Non-Small-Cell Lung Cancer
  • MTAP-null Solid Tumors

Interventions

  • AnvumetostatDrug

    Administered PO

  • IDE397Drug

    Administered PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of Participants Experiencing Dose Limiting Toxicities (DLTs)Time frame: Day 1 up to Day 21
  2. Part 1: Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)Time frame: Day 1 up to approximately 2.5 years
  3. Part 1: Number of Participants Experiencing Serious Adverse Events (SAEs)Time frame: Day 1 up to approximately 2.5 years
  4. Part 2: Objective Response (OR) per modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1Time frame: Day 1 up to approximately 2.5 years

Locations

27 sites in 7 countries. Site status is shown where the registry gives one.

  • City of Hope National Medical Center

    Duarte, California

  • Sarah Cannon Research Institute

    Denver, Colorado

  • Community Health Network MD Anderson Cancer Center - North

    Indianapolis, Indiana

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Health Partners Cancer Center at Regions Hospital

    Saint Paul, Minnesota

  • Astera Cancer Care

    East Brunswick, New Jersey

  • New York University Grossman School of Medicine and New York University Langone Hospitals

    New York, New York

  • Columbia University Irving Medical Center

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Duke University

    Durham, North Carolina

  • Prisma Health Upstate

    Greenville, South Carolina

  • University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Next Oncology

    Irving, Texas

  • The Queen Elizabeth Hospital

    Woodville South, South Australia, Australia

  • Monash Medical Centre

    Clayton, Victoria, Australia

  • Cross Cancer Institute

    Edmonton, Alberta, Canada

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada

  • Rigshospitalet

    Copenhagen, Denmark

  • Seoul National University Bundang Hospital

    Seongnam-si, Gyeonggi-do, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Severance Hospital Yonsei University Health System

    Seoul, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • Hospital Universitario Ramon y Cajal

    Madrid, Spain

  • Hospital Universitari Vall d Hebron

    Barcelona, Catalonia, Spain

  • National Cheng Kung University Hospital

    Tainan, Taiwan

  • National Taiwan University Hospital

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.